Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients.
Ji Eun ParkMi Jeong HongShin Yup LeeJang Hyuck LeeJin Eun ChoiHyo-Gyoung KangSook Kyung DoJi Yun JeongKyung Min ShinWon Kee LeeSun Ha ChoiYong Hoon LeeHye Won SeoSeung Soo YooJaehee LeeSeung Ick ChaChang Ho KimJae Yong ParkPublished in: Pharmacogenomics and personalized medicine (2021)
Genetic variants in miRNA binding sites, especially NUP62 rs9523A>G, may be useful in predicting the clinical outcomes of EGFR-mutant lung adenocarcinoma patients treated with EGFR-TKIs.